MagForce Nanotechnologies AG, the Berlin-based medical nanotechnology company majority owned by Nanostart AG, has submitted its application for the European regulatory approval of its Nano-Cancer® therapy. The application is based on the successful results of recent clinical trials involving patients with recurrent glioblastoma, an especially aggressive form of brain tumor…
(read the story…)

People who looked at this item also looked at…

• Step Forward For Nanotechnology: Controlled Movement Of Molecules (Science Daily)
• Scientists Solve Mystery Of Nanopillar Formations (redOrbit)
• Better control of carbon nanotube ‘growth’ promising for future electronics (PhysOrg)
• Shelby SuperCars aims for ‘world’s fastest production electric car’ with ‘Ultimate Aero EV’ (AME Info)
• All-American Zero-Emission Electric Bus Debuts On Capitol Hill (PollutionOnline)

Related items

• MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy (News-Medical-Net)
• MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials (News-Medical-Net)
• Nanostart Majority-Owned MagForce Announces Successful Completion of Final Clinical Trials For Nano-Cancer® Therapy (Business Wire via Yahoo! Finance)
• MagForce Nanotechnologies Completes Patient Recruitment For Pivotal Glioblastoma Study (Medical News Today)
• MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study (Business Wire via Yahoo! Finance)

Tags: application, Berlin-based, brain tumor, cancer, cancer therapy, magforce, medical nanotechnology, nano, Nano-Cancer, nanos, nanostart ag, nanotech, nanotechnologie, nanotechnologies, nanotechnology, nanotechnology company, recurrent glioblastoma, Technology

This entry was posted on December 3, 2009 at 1:50 pm and is filed under Business.